Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As the most common cancer and one of the leading causes of
cancer-associated
mortality, breast cancer continues to need more key molecules to regulate its progression. F-box and leucine-rich repeat protein 19 antisense RNA 1 (known as
FBXL19
-AS1) is a long non-coding RNA (lncRNA) which has been reported as an oncogene in several types of human cancers. However, the specific downstream targets of
FBXL19
-AS1 remain unknown. In this study, we set out to find more reliable downstream molecules of
FBXL19
-AS1 in breast cancer.
FBXL19
-AS1 was expressed at a high level in breast cancer cells. Loss-of-function experiments revealed that silencing
FBXL19
-AS1 could impair cell proliferation and induce cell apoptosis in breast cancer. In addition, the location of
FBXL19
-AS1 in the cytoplasm was detected by fluorescent in situ hybridization assay, while
FBXL19
-AS1 regulated the expression of Forkhead box M1 (FOXM1) by directly absorbing miR-876-5p. Through rescue assays, it was observed that FOXM1 overexpression recovered the inhibited tumor growth caused by
FBXL19
-AS1 downregulation. We affirmed the function of
FBXL19
-AS1 in breast cancer and described the mechanism of the
FBXL19
-AS1/miR-876-5p/FOXM1 axis. The current work presents the molecular mechanism which underlies
FBXL19
-AS1 in breast cancer and suggests a comprehensive, feasible
FBXL19
-AS1-mediated therapeutic approach for treating breast cancer.
...
PMID:FBXL19-AS1 promotes cell proliferation and inhibits cell apoptosis via miR-876-5p/FOXM1 axis in breast cancer. 3169 1
